Curis Provides First Quarter 2026 Business Update (Curis Press Release) - May 12, 2026 - "Upcoming Milestones: (i) Curis expects to announce the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, with data expected in December 2026; (ii) Also, the Company expects updated emavusertib clinical data from the TakeAim Lymphoma combination study with ibrutinib in patients with R/R PCNSL in the first half of 2027."
P1/2 data • Chronic Lymphocytic Leukemia • CNS Lymphoma
|